Clinical effects of botulinum toxin A and phenol block on gait in children with cerebral palsy

Am J Phys Med Rehabil. 2004 Apr;83(4):284-91. doi: 10.1097/01.phm.0000118038.02326.ca.

Abstract

Objective: To compare the treatment effectiveness of botulinum toxin type A (BTX-A) and phenol blocks in managing lower limb spasticity and gait dysfunction in children with cerebral palsy.

Design: This is a case-controlled study that took place in a tertiary center's gait laboratory. A total of 27 ambulatory children with cerebral palsy spastic diplegia, aged from 3 to 7 yrs, and 20 normal children were recruited into this study. Sixteen children with cerebral palsy received BTX-A injections, and 11 received phenol motor point blocks. Gait analyses were assessed by a portable computer-assisted system (Computer DynoGraphy, Infotronic, The Netherlands). Both the BTX-A and phenol groups received gait analysis at 1 wk before and 2 mos after injection treatments.

Results: Significant improvements in gait variables of velocity and cadence were noted in children with cerebral palsy after BTX-A injections as compared with the phenol block group. Gaitline and cyclogram patterns also improved significantly in the BTX-A group. The adverse clinical effects of BTX-A injections were less severe as compared with phenol injections.

Conclusions: BTX-A injections demonstrated superior treatment effects in improving gait variables and patterns in children with spastic diplegia as compared with phenol blocks. BTX-A injections also revealed fewer clinical side effects and were well tolerated by children with cerebral palsies.

Publication types

  • Comparative Study

MeSH terms

  • Botulinum Toxins, Type A / administration & dosage*
  • Case-Control Studies
  • Cerebral Palsy / complications*
  • Child
  • Child, Preschool
  • Electromyography
  • Female
  • Gait / drug effects*
  • Humans
  • Injections, Intramuscular
  • Lower Extremity
  • Male
  • Muscle Spasticity / diagnosis
  • Muscle Spasticity / drug therapy*
  • Muscle Spasticity / etiology
  • Neuromuscular Agents / administration & dosage*
  • Neuromuscular Blockade / methods*
  • Phenol / administration & dosage*
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Phenol
  • Botulinum Toxins, Type A